XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer

202315 citationsJournal Articlegold Open Access

Authors

Kurt A. Jenkins · City Of Hope National Medical Center

Miso Park · City Of Hope National Medical Center

Magali Pederzoli-Ribeil · Xilio Therapeutics (United States)

Uğur Eskiocak · Xilio Therapeutics (United States)

Parker Johnson · City Of Hope National Medical Center

Wilson Guzman · Xilio Therapeutics (United States)

M. A. McLaughlin

Abstract

These data demonstrate that XTX101 retains the full potency of an Fc-enhanced CTLA-4 antagonist within the TME while minimizing the activity in non-tumor tissue, supporting the further evaluation of XTX101 in clinical studies.

Topics & Keywords

Monoclonal and Polyclonal Antibodies Research Peptidase Inhibition and Analysis Inflammatory mediators and NSAID effects

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal for ImmunoTherapy of Cancer

Volume 11, Issue 12, pp. e007785-e007785

DOI: 10.1136/jitc-2023-007785

Field-Weighted Citation Impact: 3.44